Research / CRDO / Fundamental state Inspectable configuration
State dimensions Filing 0001628280-26-060111 General Corporate
Capex intensity 6th Own-history percentile · N=17
Evidence method Level · gp.fundamentals.capex_revenue_ratio
1.52% · OPTIONAL · VALID
Operating cash generation 71th Own-history percentile · N=17
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
18.84% · OPTIONAL · VALID
Revenue growth 57th Own-history percentile · N=14
Evidence method Yoy · gp.fundamentals.revenue
114.73% · CORE · VALID
Inventory pressure 67th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
65.35% · OPTIONAL · VALID
Gross margin 72th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.gross_margin
64.53% · CORE · VALID
Operating margin 78th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.operating_margin
25.20% · CORE · VALID
R&D intensity 22th Own-history percentile · N=18
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
23.91% · OPTIONAL · VALID
SBC intensity 72th Own-history percentile · N=18
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
18.37% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 19 states Self-history eligible
Jan 31, 2022 0/5 normalized Level 3 Apr 30, 2022 0/7 normalized Level 3 Jul 30, 2022 0/7 normalized Level 3 Oct 29, 2022 0/7 normalized Level 3 Jan 28, 2023 0/8 normalized Level 3 Apr 29, 2023 0/8 normalized Level 3 Jul 29, 2023 0/8 normalized Level 3 Oct 28, 2023 0/8 normalized Level 3 Jan 27, 2024 5/8 normalized Level 3 Apr 27, 2024 7/8 normalized Level 3 Aug 3, 2024 7/8 normalized Level 3 Nov 2, 2024 7/8 normalized Level 3 Feb 1, 2025 8/8 normalized Level 3 May 3, 2025 8/8 normalized Level 3 Aug 2, 2025 8/8 normalized Level 3 Nov 1, 2025 8/8 normalized Level 3 Jan 31, 2026 8/8 normalized Level 3 May 2, 2026 8/8 normalized Level 3 Aug 1, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Capex Intensity Decreased
Previous 4.29%
Current 1.52%
Delta -2.77% Cash Generation Decreased
Previous 34.78%
Current 18.84%
Delta -15.94% Growth Decreased
Previous 205.68%
Current 114.73%
Delta -90.95% Inventory Pressure Increased
Previous 18.79%
Current 65.35%
Delta 46.57% Margin Decreased
Previous 68.04%
Current 64.53%
Delta -3.51% Profitability Decreased
Previous 33.33%
Current 25.20%
Delta -8.13% R And D Intensity Increased
Previous 20.93%
Current 23.91%
Delta 2.98% Sbc Intensity Increased
Previous 13.68%
Current 18.37%
Delta 4.69% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Nov 1, 2025
Similarity 77%
Compared 8 dimensions
Coverage 100% Growth 33.8 · Margin 27.8 · Profitability 22.2 · Sbc Intensity 12.2 · Capex Intensity 29.8 · Cash Generation 15.1 · R And D Intensity 22.2 · Inventory Pressure 13.3 May 3, 2025
Similarity 72%
Compared 8 dimensions
Coverage 100% Growth 31.7 · Margin 27.8 · Profitability 14.5 · Sbc Intensity 10.7 · Capex Intensity 19.1 · Cash Generation 12.7 · R And D Intensity 14.5 · Inventory Pressure 59.0 May 2, 2026
Similarity 72%
Compared 8 dimensions
Coverage 100% Growth 27.5 · Margin 21.9 · Profitability 16.3 · Sbc Intensity 25.2 · Capex Intensity 6.6 · Cash Generation 16.9 · R And D Intensity 16.3 · Inventory Pressure 60.8 Jan 27, 2024
Similarity 65%
Compared 5 dimensions
Coverage 63% Margin 27.8 · Profitability 27.8 · Sbc Intensity 2.8 · R And D Intensity 52.8 · Inventory Pressure 41.7 Nov 2, 2024
Similarity 57%
Compared 7 dimensions
Coverage 88% Margin 27.8 · Profitability 32.3 · Sbc Intensity 18.7 · Capex Intensity 94.1 · Cash Generation 9.4 · R And D Intensity 23.2 · Inventory Pressure 39.4 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.